Lethbridge research projects to be presented at European College of Sports Science Conference
Loading the player instance is taking more time than usual
Loading the player instance is taking more time than usual
Three research projects exploring the connection between physical exercise and cognitive function, led by a Lethbridge Polytechnic instructor and two University of Lethbridge students, have been selected to present their work at a conference in Italy next month.
Simon Schaerz, Xander Fox and David Selles took part in three projects to demonstrate how physical activity aids in building cognitive skills, particularly in youth.
One of the projects looked at physical activity to improve executive function and memory flexibility with the polytechnic's e-sports team.
Another project focused on creating a framework to help teachers in training develop physical education programs that support students' executive function.
The third project examined the use of progressive overload in long-term exercise to improve executive function.
A trio of research projects born out of Lethbridge will be presented at the European College of Sports Science Conference in Italy next month.
A trio of research projects born out of Lethbridge will be presented at the European College of Sports Science Conference in Italy next month.
'It's a really cool opportunity to go overseas and get to present. … Not only to share my research with people from multiple different countries and backgrounds in areas of research, but to also get to take in a lot of research from other people that have various backgrounds,' said Fox, University of Lethbridge Bachelor of Science graduate.
'We don't have the capacity to do these massive studies, but just the small studies, literature reviews, that are really meaningful in the sense of training future to-be researchers is really valuable,' said Schaerz, Lethbridge Polytechnic Centre for Health and Wellness instructor.
The trio will present their projects at the European College of Sports Science Conference, July 1-4 in Italy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 hours ago
- Globe and Mail
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025. Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0402 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 1992038 To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. Access the audio webcast - Click here: Access Webcast A conference call replay will be available by using the following link: Contact : IR@ About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and costeffective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed more than 5,600 people in over 35 locations worldwide. For more information, visit
CTV News
a day ago
- CTV News
Alpha males are rare among our fellow primates: scientists
PARIS, France — New research on Monday contradicted the commonly held idea that males dominate females among primates, revealing far more nuanced power dynamics in the relationships of our close relatives. 'For a long time we have had a completely binary view of this issue: we thought that a species was either dominated by males or females -- and that this was a fixed trait,' Elise Huchard, a primatologist at the University of Montpellier in France, told AFP. 'Recently, this idea has been challenged by studies showing that the truth is much more complicated,' said the lead author of a new study published in the journal PNAS. The French-German team of researchers combed through scientific literature for interactions between male and female primates that revealed their hierarchical relationships. These included aggression, threats and signs of dominant or submissive behaviour, such as when one primate spontaneously moved out of the way of another. Over five years, the team gathered data from 253 populations across 121 primate species, including a range of monkeys, lemurs, tarsiers and lorises. They found that confrontations between members of the opposite sex were much more frequent than had been previously thought. On average, more than half of these interactions within a group involved a male and a female. Males clearly dominating females, which was defined as winning more than 90 percent of these confrontations, was only observed in 17 percent of the populations. Among this minority were baboons and chimpanzees, which are the closest living relatives to humans. Clear female domination was recorded in 13 percent of the primate populations, including lemurs and bonobos. This meant that for 70 percent of the primates, either males or females could be at the top of the pecking order. Battle of the sexes When male domination was particularly pronounced, it was usually in a species where males have a clear physical advantage, such as bigger bodies or teeth. It was also more common among ground-bound species, in which females are less able to run and hide compared to their relatives living in the trees. Females, meanwhile, tended to dominate over societies when they exerted control over reproduction. For example, the genitals of female baboons swell when they are ovulating. Males jealously guard females during these few days of their menstrual cycle, making sure that other competitors cannot mate with them. However in bonobos, this sexual swelling is less obvious. 'Males never know when they are ovulating or not. As a result, (the female bonobos) can mate with whoever they want, whenever they want, much more easily,' Huchard said. Female dominance is also more common when females compete with each other, and when males provide more care for the young. In these species, females are often solitary or only live in male-female pairs. This means that monogamy is closely linked to female dominance. Can these results be extrapolated to our own species? There are a great many differences between humans and our fellow primates, Huchard emphasised. But we would broadly fall into the middle category in which neither males nor females always have strict dominance over the other. 'These results corroborate quite well with what we know about male-female relationships among hunter-gatherers, which were more egalitarian than in the agricultural societies that emerged later' in human history, Huchard said.
National Post
a day ago
- National Post
CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology
Article content BAAR, Switzerland — CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company's technology for investigational device exemption (IDE), which allows the pivotal clinical trial to begin at U.S. hospitals. CorFlow will now prepare these clinical trial sites to receive CorFlow systems, undergo training and begin enrolling patients being treated for heart attacks. Article content The IDE Pivotal Trial, MOCA-II, is intended to prospectively validate the diagnostic accuracy of the proprietary CorFlow CoFl system in determining the presence or absence of microvsacular obstruction (MVO) during a primary PCI procedure. The primary endpoint compares the CoFI diagnostic reading to a reference standard of diagnosis by a cardiac MRI scan. The trial is approved to enroll over 200 STEMI patients at prestigious research institutions in both the United States and Europe. Article content Article content Having successfully completed the first-in-human MOCA-I trial in 2024, the MOCA-II study is the next critical step to bringing this unique technology into the hands of interventional cardiologists globally for the rapid diagnosis of MVO in heart attack patients. This in turn can enable new treatments and care pathways to the large MVO patient population with high rates of adverse clinical outcomes today. The CorFlow technology is designed to both diagnose MVO, plus serve as a localized drug delivery system for diagnostic and therapeutic agents, which is being researched independently. Article content According to the US government Centers for Disease Control and Prevention, someone has a heart attack every 30 seconds in the USA, with about 800,000 cases reported annually in the country. Incidence and prevalence are similarly high in Europe. More than half of STEMI heart attack patients are shown to have MVO, and previous research has demonstrated that the presence of MVO is a major driver of adverse events. Currently, there are no technologies approved to diagnose MVO during an acute coronary intervention, and there are no approved therapeutic devices that specifically address MVO in the United States or Europe. Heart attacks and related heart disease remains a leading cause of death and disability worldwide. Article content Paul Mead, CEO of CorFlow, said, 'The long history of interventional cardiology and heart attack care breakthroughs – going back over 100 years – is one of the great success stories of medical care progress, but the pioneers and luminaries of the field all agree that the work is unfinished. The majority of acute STEMI survivors have MVO, and current outcomes for these patients are shockingly poor. We aim to bring this issue to light and show you can do something about it. This milestone brings us all one step closer to delivering on the promise to improving care for these people where we know we can do better.' Article content MOCA-II is being led by world-renowned experts in heart attack care, Dr. Timothy Henry at The Christ Hospital in Cincinnati, Ohio (United States) and Professor Marco Valgimigli at Cardiocentro Ticino Institute, Lugano (Switzerland), who collectively have been published in over 1,000 peer-reviewed manuscripts in cardiovascular research. Article content Dr. Tim Henry said, 'As an interventional cardiologist involved for decades in managing and researching STEMI patients, I am excited to get going on this pivotal trial with technology that could make such a significant impact to the outcome of our patients. I believe strongly that knowing with high confidence who has MVO at the point of care during a primary PCI procedure can make an immediate difference in how we manage our patients.' Professor Valgimigli added, 'Having played a significant part in MOCA-I first in human trial, I am thrilled to see the second-generation technology now available for the pivotal trial and am looking forward to contributing further to the scientific understanding of MVO in real time. While the medical community has diverse opinions on how to treat these patients, there is no question that proper diagnosis is the first step we need. I am optimistic that getting the CorFlow technology approved for everyday use by our peer interventional cardiologists can help move the field forward.' Article content About CorFlow Therapeutics: Headquartered in Baar, Switzerland, with subsidiary operations in both Italy and the United States. The company is venture capital funded with an international VC firm syndicate, most recently with a Series B financing round announced in September 2024. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications for the unique patented technology. Article content Article content Article content
